Table 1. Pro-thrombotic agents and relevant genetic polymorphisms.

Drug	Gene polymorphism	Protein role	Effect
OCPs	FSAP 1601GG	Activates factor VII	Increased factor VII activation
	CYP3A4 haplotype A or B	Metabolizes ethinylestradiol	Increased VTE risk
	UGT2B7 haplotype D	Metabolizes ethinylestradiol	Increased sex-hormone-binding-globulin, increased VTE risk
	F11 rs2289252-A	Factor XI	Increased VTE risk
Bevacizumab	VEGFA rs2010963-CC	Mediates angiogenesis	Increased thrombo-hemorrhagic events in glioma patients

OCPs, oral contraceptives; VTE, venous thromboembolism.